What is Systemic Lupus Erythematosus (SLE)?
Systemic Lupus Erythematosus (SLE), commonly called Lupus, is a complex, protean, and potentially life-threatening autoimmune disease in which the immune system produces a wide array of autoantibodies that attack virtually every organ system in the body. It is the archetypal systemic autoimmune disease, capable of mimicking almost any other illness, which is why it is historically called "The Great Imitator."
SLE is characterised by a relapsing-remitting course — patients experience periods of flares (active disease causing organ damage) punctuated by periods of relative remission. The challenge of SLE lies not just in controlling active disease, but in preventing long-term organ damage from both the disease itself and the side effects of the immunosuppressive medications used to treat it.
The malar "butterfly" rash across the cheeks and nose bridge — one of the most recognisable cutaneous manifestations of Lupus.
Who Does Lupus Affect?
Lupus disproportionately affects women of childbearing age (15-45 years), with a female-to-male ratio of 9:1. It is more common and more severe in people of Asian, African, and Hispanic descent. The peak incidence in India occurs in young women aged 20-40 years, making this a disease that strikes at the most productive years of a woman's life.
The Many Faces of Lupus: Organ Manifestations
Lupus can affect virtually any organ. The most important manifestations include:
- Skin: Malar butterfly rash (acute cutaneous lupus), discoid lupus (scarring skin lesions), photosensitivity, oral ulcers, and hair loss (alopecia).
- Joints: Non-erosive inflammatory arthritis affecting small and large joints symmetrically, often similar to early RA.
- Kidneys (Lupus Nephritis): The most serious and prognostically important complication. Occurs in 50-60% of patients. Ranges from mild proteinuria to rapidly progressive glomerulonephritis (diffuse proliferative lupus nephritis) that can lead to end-stage renal failure within weeks if untreated.
- Blood: Haemolytic anaemia, leukopenia (low white cells), and thrombocytopenia (low platelets) are hallmarks.
- Brain (Neuropsychiatric Lupus): Ranges from cognitive dysfunction ("lupus fog") and depression to psychosis, seizures, and stroke.
- Lungs: Pleuritis, lupus pneumonitis, pulmonary hypertension.
- Heart: Pericarditis, Libman-Sacks endocarditis, and accelerated atherosclerosis.
- Antiphospholipid Syndrome: Present in 30-40% of SLE patients — increases the risk of blood clots and pregnancy loss.
Comprehensive antibody panels including ANA, anti-dsDNA, and complement levels are essential for diagnosing and monitoring Lupus activity.
🔬 The ANA Test: What It Means and Doesn't Mean
ANA (Antinuclear Antibody) testing is the initial screening test for lupus. However, a positive ANA is present in 20-30% of healthy individuals at low titres. A positive ANA alone does NOT mean you have lupus. The diagnosis requires a positive ANA plus clinical features and specific antibodies. Anti-dsDNA and anti-Sm antibodies, on the other hand, are highly specific for SLE and correlate with disease activity (particularly nephritis).
Diagnosis: The 2019 EULAR/ACR Classification Criteria
SLE diagnosis uses the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria, which assigns weighted scores to clinical domains (constitutional, haematological, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunological domains (antiphospholipid antibodies, complement levels, specific SLE antibodies). A score of ≥10 in a patient with a positive ANA classifies the diagnosis.
Key investigations include: ANA (screening), Anti-dsDNA, Anti-Sm, Anti-Ro, Anti-La, antiphospholipid antibodies, Complete blood count, complement levels (C3, C4), and urine routine for protein and red cell casts (indicating nephritis).
Treatment: Protecting Organs, Enabling Life
SLE management requires a careful balance between controlling autoimmunity and avoiding the toxicities of immunosuppression. The cornerstone of all lupus management is Hydroxychloroquine — an antimalarial that reduces lupus flares, prevents organ damage, and improves survival. It is given to virtually all SLE patients regardless of disease severity.
For more active disease, corticosteroids (Prednisolone) are used to rapidly control flares, while steroid-sparing immunosuppressants (Azathioprine, Mycophenolate Mofetil) provide long-term disease control. For lupus nephritis, Mycophenolate Mofetil or Cyclophosphamide are standard induction therapies. Belimumab (an anti-BAFF biologic) and Voclosporin are newer targeted therapies approved specifically for SLE and lupus nephritis.
Dr. Prateek's Approach to Lupus
SLE requires a knowledgeable physician who can decode its complexity and guide patients through the uncertainty of a chronic, relapsing disease. Dr. Prateek Deo has managed hundreds of lupus patients at PGIMER — one of India's largest referral centres for complex SLE — and brings that high-level expertise to Bhopal.
Organ Damage Prevention
Our primary goal is to prevent irreversible organ damage — particularly lupus nephritis — through early diagnosis, urine monitoring, and aggressive early treatment of flares.
Steroid Minimisation
We actively work to minimise corticosteroid doses using steroid-sparing agents, protecting patients from long-term steroid side effects like osteoporosis and diabetes.
Pregnancy Counselling
Lupus requires careful planning around pregnancy. We provide pre-conception counselling, medication adjustments, and close monitoring throughout pregnancy to ensure the best outcomes for both mother and baby.
Cardiovascular Protection
SLE accelerates atherosclerosis. We proactively monitor and manage blood pressure, cholesterol, and blood sugar — the modifiable cardiovascular risk factors.